Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against GSK plc for Alleged Securities Law Violations
On February 17, 2025, Bronstein, Gewirtz & Grossman, LLC, a leading national securities fraud law firm, announced that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE:GSK) and certain of its officers. The lawsuit alleges that the defendants violated the federal securities laws during the Class Period, which spans from February 5, 2020, to August 14, 2022.
Class Definition
This lawsuit aims to recover damages for all persons and entities that purchased or otherwise acquired GSK’s American Depositary Receipts (ADRs) during the Class Period. The plaintiffs allege that the defendants provided false and misleading statements and failed to disclose material information regarding the Company’s financial condition and business operations.
Impact on Individual Investors
If you are an individual investor who purchased or otherwise acquired GSK ADRs during the Class Period, you may be eligible to participate in this class action lawsuit. The complaint alleges that the defendants made false and misleading statements, causing investors to purchase GSK securities at artificially inflated prices. As a result, investors may have suffered significant financial losses when the truth was revealed.
- If you wish to act as a lead plaintiff, you must meet certain requirements and must file an application with the court no later than the lead plaintiff deadline. You do not need to seek approval from your broker or law firm to join the case.
- If you are a member of the Class, you can choose to do nothing and remain an absent class member. The class will be represented by the lead plaintiff and their counsel.
- If you wish to opt-out of the class, you must do so before the opt-out deadline. Opting out means you will no longer be part of the class and will not be eligible to participate in any potential recovery.
Impact on the World
The filing of this class action lawsuit against GSK plc may have significant implications for the pharmaceutical industry and investor confidence. If the allegations are proven true, it could result in increased scrutiny of other companies in the sector, as well as increased pressure on regulators to enforce securities laws more vigorously. Additionally, investors may become more cautious when considering investments in pharmaceutical companies, potentially leading to a decrease in stock prices and market volatility.
Conclusion
The filing of this class action lawsuit against GSK plc and certain of its officers is a significant development for investors who purchased or otherwise acquired the Company’s ADRs during the Class Period. The allegations, if proven true, could result in significant damages for affected investors. For those interested in participating in the lawsuit, it is essential to take action before the deadlines outlined in the complaint. The potential impact on the pharmaceutical industry and investor confidence remains to be seen, but it is clear that this lawsuit will be closely watched by industry observers and investors alike.
For more information about the class action lawsuit against GSK plc, please visit
* This notice is not a substitute for legal advice. If you have any questions, please consult with a lawyer.
